1. Report Overview
1.1 Gastric Cancer Therapeutics: Market Overview
1.2 Global Gastric Cancer Therapeutics Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Main Questions Answered by This Analytical Study
1.6 Who is This Report For?
1.7 Methods of Research and Analysis
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2. Introduction to Gastric Cancer Treatment
2.1 Stomach Cancer: An Overview
2.2 Treatments for Stomach Cancer
2.3 Defining the Gastric Cancer Therapies Market
3. Leading Stomach Cancer Drugs
3.1 Herceptin (trastuzumab) – Roche: The First Targeted Drug Approved as a Gastric Cancer Treatment
3.1.1 Herceptin: Treatment of HER2+ Cancer
3.1.2 Herceptin: Method of Administration and Side Effects
3.1.3 ToGA: Pivotal Herceptin Study Led to Approvals
3.1.4 ToGA Trial Results
3.1.4.1 Further Possibilities from the ToGA Results
3.1.5 Herceptin Revenue Forecast 2015-2026: Losing Battle with Biosimilar Trastuzumab
3.2 Cyramza (ramucirumab) – Eli Lilly
3.2.1 REGARD and RAINBOW: Pivotal Cyramza Clinical Trials
3.2.2 Cyramza: VEGF Targeting for the Inhibition of Angiogenesis
3.2.3 Cyramza’s Development: Potential as a Combination Treatment
3.2.4 Cyramza Revenue Forecast 2015-2026
3.3 Taxotere (docetaxel) – Sanofi
3.3.1 Taxotere Revenue Forecast 2015-2026
3.4 Xeloda (capecitabine) – Roche
3.4.1 Xeloda Revenue Forecast 2015-2026
3.5 Abraxane (paclitaxel protein-bound particles) – Celgene/ Taiho Pharmaceutical/Otsuka Pharmaceutical
3.5.1 Abraxane Revenue Forecast 2015-2026
3.6 TS-1 (S-1/Teysuno) – Taiho Pharmaceutical/Otsuka Pharmaceutical
3.6.1 TS-1 Revenue Forecast 2015-2026
3.7 Apatinib (YN968D1) – Jiangsu Hengrui Medicine/LSK BioPartners/Bukwang Pharmaceutical Company
3.7.1 Apatinib Revenue Forecast 2015-2026
4. The Gastric Cancer Treatment R&D Pipeline Analysis 2016-2026
4.1 The Importance of R&D in the Gastric Cancer Treatment Industry
4.2 Perjeta (pertuzumab) – Roche – A Novel HER2 Targeting Mechanism
4.3 Opdivo (nivolumab/ONO-4538) – Bristol-Myers Squibb
4.4 Keytruda (pembrolizumab/MK3475) – Merck/MSD
4.5 TAS-118 – Taiho Pharmaceutical/Otsuka Pharmaceuticals
4.6 TAS-102 – Taiho Pharmaceutical/Otsuka Pharmaceuticals/Servier
4.7 NeuVax (nelipepimut-S) – Galena Biopharma/Dr. Reddy’s Laboratories
4.8 Ipatasertib (GDC-0068/RG7440) – Genentech/Roche/Array BioPharma
4.9 Durvalumab (MEDI4736) – AstraZeneca/MedImmune
4.10 Avelumab- (MSB0010718C) – Merck KGaA/Pfizer
4.11 Claudiximab (IMAB362) – Ganymed Pharmaceutical
4.12 Napabucasin (BBI608) – Boston Biomedical
4.13 AZD4547 – AstraZeneca
4.14 Dovitinib (TKI258) – Novartis
4.15 The Future of the Gastric Cancer Treatment Landscape: Other Compounds of Future Interest
5. Global Gastric Cancer World Market 2015 to 2026: Forecasts and SWOT Analysis
5.1 The Global Gastric Cancer Treatment Market Forecast 2015-2026
5.2 World Revenue Forecasts 2015-2026: Changing Market Shares for the Gastric Cancer Treatment Market
5.3 Chemotherapy Segment Forecast, 2015-2026
5.4 Monoclonal Antibodies Segment Forecast, 2015-2026
5.5 Angiogenesis Inhibitors Segment Forecast, 2015-2026
5.6 Drivers and Restraints of the Gastric Cancer Treatment Market 2015 to 2026
5.6.1 Factors Driving Growth in the Gastric Cancer Treatment Market 2015 to 2026
5.6.1.1 A Rise in the At-Risk Population Will Drive Growth
5.6.1.2 Premium-Pricing of Drugs Will Generate Revenue
5.6.1.3 There is High Unmet Need for Novel Treatments to Improve Poor Prognosis
5.6.1.4 Biomarker Development is Critical to Improving Diagnosis and Prognosis of Gastric Cancer
5.6.1.5 Combination Therapies: Lowering Associated Toxicities and Improving the Safety Profile for Treatments
5.6.2 Factors Restraining the Gastric Cancer Treatment Market 2015 to 2026
5.6.2.1 Loss of Patent Protection Will Open the Market to Generic and Biosimilar Erosion
5.6.2.2 Affordability of Treatment Will Restrain Market Growth Because of Healthcare Budgets
5.6.2.3 Patients are Developing Resistance to Treatment
5.7 SWOT Analysis of the Gastric Cancer Treatment Market 2015 to 2026
6. Leading National Markets for the Gastric Cancer Treatment Market 2015-2026
6.1 Regional Breakdown of the World Gastric Cancer Treatment Market
6.2 World Gastric Cancer Treatment Market: Regional Forecasts 2015-2026
6.2.1 How Will Regional Market Shares Change to 2026?
6.3 The US Gastric Cancer Treatment Market 2015 to 2026
6.4 The EU5 Gastric Cancer Treatment Market 2015 to 2026
6.4.1 The Gastric Cancer Treatment Market in Germany to 2026
6.4.2 The Gastric Cancer Treatment Market in Italy to 2026
6.4.3 The Gastric Cancer Treatment Market in Spain to 2026
6.4.4 The Gastric Cancer Treatment Market in France to 2026
6.4.5 The Gastric Cancer Treatment Market in UK to 2026
6.5 The Japanese Gastric Cancer Treatment Market 2015-2026
6.6 The Gastric Cancer Treatment Market in the Emerging Market: BRIC Market Forecast 2015-2026
6.6.1 The Gastric Cancer Treatment Market in China to 2026
6.6.2 The Gastric Cancer Treatment Market in Brazil to 2026
6.6.3 The Gastric Cancer Treatment Market in Russia to 2026
6.6.4 The Gastric Cancer Treatment Market in India to 2026
7. Research Interview
7.1 Interview with Dr Jun Cai, MD, PhD, Senior Research Fellow, Cardiff China Research Collaborative, Cardiff University, Cardiff, Wales, UK
7.1.1 Biomarkers: An Opportunity in Gastric Cancer Treatment
7.1.2 Challenges in Developing Gastric Cancer Treatments
7.1.3 The Benefits of Using Biomarkers
7.1.4 Targeted Treatment: VEGF Inhibitors
8. Conclusions
8.1 The World Gastric Cancer Treatment Market in 2015
8.2 Market Share Distribution Will Differ Over the Forecast Period
8.3 Leading Gastric Cancer Treatment Drug Companies
8.4 National Market Segments: Changes in Market Share Over the Forecast Period
8.5 Concluding Remarks: The Future of the Gastric Cancer Treatment Market
Table 3.1 FDA Approved Indications of Herceptin
Table 3.2 Selected Approval Dates for Herceptin for Gastric Cancer Treatment by Region
Table 3.3 Herceptin Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 3.4 Herceptin Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 3.5 FDA Approvals for Cyramza
Table 3.6 Selected Approvals for Cyramza for Gastric Cancer Treatment by Region
Table 3.7 Selected Cyramza Phase 1 and 2 Clinical Trials, 2016
Table 3.8 Cyramza Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 3.9 Cyramza Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 3.10 Taxotere Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 3.11 Taxotere Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 3.12 Xeloda Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 3.13 Xeloda Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 3.14 Abraxane Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 3.15 Abraxane Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 3.16 TS-1 Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 3.17 TS-1 Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 3.18 Selected Clinical Trials for Apatinib, 2016
Table 3.19 Apatinib Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 3.20 Apatinib Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 4.1 Selected Gastric Cancer Pipeline Developments, 2016
Table 4.2 HER2 Structure
Table 4.3 S-1 Structure, 2016
Table 4.4 Other Compounds of Interest for Gastric Cancer Treatment, 2016
Table 5.1 Global Gastric Cancer Treatment Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
Table 5.2 Global Gastric Cancer Treatment Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
Table 5.3 Top Three Gastric Cancer Treatment Drugs by Revenue ($bn), 2015
Table 5.4 Global Market for Gastric Cancer Drug Treatments: Revenues ($bn) and Market Shares (%) by Class, 2015
Table 5.5 Global Market Forecast for Gastric Cancer Treatment Drugs by Class: Market Sizes ($bn), Annual Growth Rates (%), CAGR (%), 2015-2020
Table 5.6 Global Market Forecast for Gastric Cancer Treatment Drugs by Class: Market Sizes ($bn), Annual Growth Rates (%), CAGR (%), 2021-2026
Table 5.7 Global Market Forecast for Gastric Cancer Treatment Drugs by Class: Changing Market Shares (%), 2015-2026
Table 5.8 Chemotherapy Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 5.9 Chemotherapy Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 5.10 Monoclonal Antibodies Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 5.11 Monoclonal Antibodies Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 5.12 Angiogenesis Inhibitors Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 5.13 Angiogenesis Inhibitors Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 5.14 SWOT: Strengths, Weaknesses, Opportunities and Threats in the Gastric Cancer Treatment Market, 2016-2026
Table 6.1 Gastric Cancer Treatment Market: Revenues ($bn) and Market Shares (%) by Region, 2015
Table 6.2 Gastric Cancer Treatment Market: Regional Forecasts, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 6.3 Gastric Cancer Treatment Market: Regional Forecasts, Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 6.4 US Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 6.5 US Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 6.6 EU5 Gastric Cancer Treatment Market: Revenue ($bn) and Market Share (%) by Leading Country, 2015
Table 6.7 EU5 Gastric Cancer Treatment National Market Forecasts: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 6.8 EU5 Gastric Cancer Treatment National Market Forecasts: Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 6.9 German Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 6.10 German Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 6.11 Italian Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 6.12 Italian Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 6.13 Spanish Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 6.14 Spanish Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 6.15 French Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 6.16 French Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 6.17 UK Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 6.18 UK Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 6.19 Japanese Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 6.20 Japanese Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 6.21 Pharma Contract Manufacturing Market: Emerging Market Revenue ($bn) and Market Share (%) by Top Country, 2015
Table 6.22 Gastric Cancer Treatment Market: Leading Emerging Market Forecasts: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 6.23 Gastric Cancer Treatment Market: Leading Emerging Market Forecasts: Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 6.24 Chinese Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 6.25 Chinese Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 6.26 Brazilian Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 6.27 Brazilian Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 6.28 Russian Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 6.29 Russian Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 6.30 Indian Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 6.31 Indian Gastric Cancer Treatment Market Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 8.1 Gastric Cancer Treatment Drugs Market Forecasts by Class: Market Size ($bn), Market Share (%), CAGR (%), 2015, 2020, and 2026
Table 8.2 Gastric Cancer Treatment Market Forecast by Region: Market Size ($bn), Market Share (%), CAGR (%), 2015, 2020, and 2026
List of Figures
Figure 1.1 Global Gastric Cancer Therapeutics Market Segmentation Overview, 2016
Figure 3.1 Herceptin Forecast: Revenue ($bn), 2015-2026
Figure 3.2 Cyramza Forecast: Revenue ($bn), 2015-2026
Figure 3.3 Taxotere Forecast: Revenue ($bn), 2015-2026
Figure 3.4 Xeloda Forecast: Revenue ($bn), 2015 -2026
Figure 3.5 Abraxane Forecast: Revenue ($bn), 2015-2026
Figure 3.6 TS-1 Forecast: Revenue ($bn), 2015-2026
Figure 3.7 Apatinib Forecast: Revenue ($bn), 2015-2026
Figure 5.1 Global Gastric Cancer Treatment Market Forecast: Revenue ($bn), 2015-2026
Figure 5.2 Global Market for Gastric Cancer Treatments: Market Shares by Class (%), 2015
Figure 5.3 Global Market Forecast for Gastric Cancer Treatment Drugs by Class: Market Sizes ($bn), 2015 to 2026
Figure 5.4 Global Market for Gastric Cancer Treatment Drugs by Class: Market Shares (%), 2020
Figure 5.5 Global Market for Gastric Cancer Treatment Drugs by Class: Market Shares (%), 2026
Figure 5.6 Chemotherapy Segment: Revenues ($bn), 2015-2026
Figure 5.7 Monoclonal Antibodies Segment: Revenues ($bn), 2015-2026
Figure 5.8 Angiogenesis Inhibitors Segment: Revenues ($bn), 2015-2026
Figure 5.9 Gastric Cancer Treatment Market: Main Drivers and Restraints, 2016-2026
Figure 6.1 Gastric Cancer Treatment Market: Share (%) by Region, 2015
Figure 6.2 Forecast of Regional and National Gastric Cancer Treatment Market, Revenue ($bn), 2015-2026
Figure 6.3 Gastric Cancer Treatment Market: Share (%) by Region, 2020
Figure 6.4 Gastric Cancer Treatment Market: Share (%) by Region, 2026
Figure 6.5 US Gastric Cancer Treatment Market Forecast: Revenue ($bn), 2015-2026
Figure 6.6 EU5 Gastric Cancer Treatment Market: Share (%) by Country, 2015
Figure 6.7 EU5 Gastric Cancer Treatment National Market Forecasts: Revenue ($bn), 2015-2026
Figure 6.8 German Gastric Cancer Treatment Market Forecast: Revenue ($bn), 2015-2026
Figure 6.9 Italian Gastric Cancer Treatment Market Forecast: Revenue ($bn), 2015-2026
Figure 6.10 Spanish Gastric Cancer Treatment Market Forecast: Revenue ($bn), 2015-2026
Figure 6.11 French Gastric Cancer Treatment Market Forecast: Revenue ($bn), 2015-2026
Figure 6.12 UK Gastric Cancer Treatment Market Forecast: Revenue ($bn), 2015-2026
Figure 6.13 Japanese Gastric Cancer Treatment Market Forecast: Revenue ($bn), 2015-2026
Figure 6.14 Gastric Cancer Treatment Market: Emerging Market Share (%) by Top Country, 2015
Figure 6.15 Forecast of the Emerging Gastric Cancer Treatment Market, Revenue ($bn), 2015-2026
Figure 6.16 Chinese Gastric Cancer Treatment Market Forecast: Revenue ($bn), 2015-2026
Figure 6.17 Brazilian Gastric Cancer Treatment Market Forecast: Revenue ($bn), 2015-2026
Figure 6.18 Russian Gastric Cancer Treatment Market Forecast: Revenue ($bn), 2015-2026
Figure 6.19 Indian Gastric Cancer Treatment Market Forecast: Revenue ($bn), 2015-2026
Figure 8.1 The Gastric Treatment Market Forecast by Class: Market Sizes ($bn), 2015, 2020, and 2026
Figure 8.2 Gastric Cancer Treatment Market Forecasts by Region: Market Size ($bn), 2015, 2020, and 2026